SK Plasma, a South Korean biologic medicine company that develops and manufactures high-quality plasma-derived medicines, intends to invest $250 million in the construction of a new blood products manufacturing facility in Jakarta, Indonesia's capital city.

The plasma fractionation facility will produce immune globulin and albumin, which will be used to treat patients with immunodeficiency diseases and haemophilia. The plant will have a capacity of one million litres of blood products per year.

SK Plasma is a subsidiary of SK Discovery, which announced in December 2022 that it would establish a bio strategy and investment division led by Kim Jung-hoon, the director of SK Chemicals' R&D centre.

SK Plasma, which has been in business since 1970, specialises in plasma-derived medicine and plasma fractionation under the founding principle of "promoting human health and protecting the environment."

SK Plasma spun off from SK Chemicals Life Science business in 2015 to become an independent company, focusing on core competencies in the plasma derivative business to improve competitiveness and accelerate global expansion.

Plasma-derived products are critical medicines for treating diseases that have a direct impact on human life, such as congenital immunodeficiency diseases and haemophilia. As a result, SK Plasma does not simply cease to generate economic value, but also plays a significant role in creating social value to protect the health of human lives.

Furthermore, in order to meet the rapidly increasing demand for plasma-derived biotherapies in both the domestic and international markets, we built the most advanced new plasma fractionation plant in Andong and began commercial production in August 2018 with KGMP approval.